Gene
G6PD
G6PD is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (3), Actionable biomarkers (3), Trial mentions (1,087), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention G6PD. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers. Not plotted: 3 with a planned future start and 15 with no date at all.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 5 dated before 1990 and 8 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 60 of 8,738 | 0.69% | not measured | |
| 2025 | 53 of 8,875 | 0.60% | not measured | |
| 2024 | 50 of 8,597 | 0.58% | not measured | |
| 2023 | 54 of 8,275 | 0.65% | 24 of 11,460 | 0.21% |
| 2022 | 38 of 8,285 | 0.46% | 30 of 13,598 | 0.22% |
| 2021 | 51 of 8,692 | 0.59% | 28 of 15,045 | 0.19% |
| 2020 | 126 of 7,640 | 1.65% | 37 of 14,459 | 0.26% |
| 2019 | 71 of 7,300 | 0.97% | 34 of 12,159 | 0.28% |
| 2018 | 68 of 6,927 | 0.98% | 39 of 11,854 | 0.33% |
| 2017 | 51 of 6,558 | 0.78% | 28 of 11,595 | 0.24% |
Showing 10 of 37 years.
Assay-provider ledger (3)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| PROTEINTECH GROUP, INC. | Reagent supplier | Clinical validationAnalytical validation | 1 | November 10, 2020 |
| SurExam Bio-Tech | Diagnostic provider | Clinical validationAnalytical validation | 1 | June 28, 2018 |
| United Diagnostics Industry | Diagnostic provider | Clinical validation | 1 | July 11, 2017 |
Actionable biomarkers (3)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| G6PD biallelic inactivation | Dabrafenib | other | No disease recorded | Cancer Genome Interpreter |
| G6PD (S218F) | Dabrafenib | other | No disease recorded | Cancer Genome Interpreter |
| G6PD (V98M) + G6PD (N156D) | Dabrafenib | other | No disease recorded | Cancer Genome Interpreter |
Trial mentions (1,087)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT04081272 | Trial biospecimen (AACT) |
| NCT03353051 | Trial biospecimen (AACT) |
| NCT02625285 | Trial biospecimen (AACT) |
| NCT00021866 | Trial biospecimen (AACT) |
| NCT02104518 | Trial biospecimen (AACT) |
Showing 5 of 1,087 trial mentions.
Target-disease associations (298)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| Adult-onset autosomal recessive sideroblastic anemia | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| Alpha-thalassemia | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| Alpha-thalassemia - intellectual disability syndrome linked to chromosome 16 | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| Alpha-thalassemia - myelodysplastic syndrome | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| Alzheimer disease | nervous system disease | Literature (Europe PMC) |
Showing 5 of 298 associations.
Vendor sourcing (3,875)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 100 Voices of Hope | Trial collaborator | Named in trial exclusion criteriaTrial eligibility criteria | : 1. Current or prior use of hydroxychloroquine or chloroquine within 6 months 2. Known hypersensitivity to hydroxychloroquine, chloroquine, or 4-aminoquino... | View trial NCT07825454 |
| 100 Voices of Hope | Trial collaborator | Mentioned in trial textTrial free-text mention | G6PD | View trial NCT07825454 |
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The variant is observed in the gnomAD v4.1.0 dataset (total allele frequency: 0.141%). Predicted Consequence/Location: Missense variant. Missense changes are... | View ClinVar record SCV002572646.3 |
| 60 Degrees Pharmaceuticals, Inc. | Trial sponsor | Named in trial exclusion criteriaTrial eligibility criteria | : * Have one of the contraindications for ARAKODA or KODATEF in the prescribing information (section 16.1) including: 1. G6PD deficiency 2. Breastfeedi... | View trial NCT04533347 |
| 60 Degrees Pharmaceuticals, Inc. | Trial sponsor | Named in trial exclusion criteriaTrial eligibility criteria | : * Glucose-6-phosphate-dehydrogenase (G6PD) deficiency * Breastfeeding * Unmanaged Psychotic disorder * Known hypersensitivity reaction to tafenoquine or o... | View trial NCT06656351 |
Showing 5 of 3,875 sourcing records.
Trial-cited literature (429)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| 14 days of high-dose versus low-dose primaquine treatment in patients with Plasmodium vivax infection in Cambodia: a randomised, single-centre, open-label efficacy study. | The Lancet. Infectious diseases | 2025 | 13 |
| High daily dose Short COurse PrimaquinE after G6PD testing for the radical cure of Plasmodium vivax malaria in Indonesia and Papua New Guinea: the SCOPE implementation study protocol. | BMC infectious diseases | 2025 | 4 |
| Impact of 2022 AAP Neonatal Hyperbilirubinemia Guidelines in a Middle-Income Country: A Single-Center Study in Thailand. | Neonatology | 2025 | 2 |
| Safety and Efficacy of 3 Alternative Regimens Against Relapsing Plasmodium vivax Malaria in Glucose 6-Phosphate Dehydrogenase-Deficient Patients in the Brazilian Amazon (ALTPRIM). | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2025 | 2 |
| High versus low dose of 14 days treatment of primaquine in <i>Plasmodium vivax</i> infected patients in Cambodia: a randomised open-label efficacy study. | medRxiv : the preprint server for health sciences | 2025 | 0 |
Showing 5 of 429 papers.
Protein variant mentions (35)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.A335T | 1 | 2015 | PMID 25741868 |
| p.A44G | 2 | 2012 to 2015 | PMID 25741868, PMID 22958163 |
| p.A578S | 1 | 2016 | PMID 27128675 |
| p.D181V | 3 | 2011 to 2015 | PMID 25741868, PMID 22958163, PMID 21849081 |
| p.D350H | 1 | 2015 | PMID 25741868 |
Showing 5 of 35 variants.
Literature-extracted relations (46)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Primaquine | Chemical | associate |
High daily dose Short COurse PrimaquinE after G6PD testing for the radical cure of Plasmodium vivax malaria in Indonesia and Papua New Guinea: the SCOPE implementation study protocol. | 2025 |
| Primaquine | Chemical | associate |
High versus low dose of 14 days treatment of primaquine in <i>Plasmodium vivax</i> infected patients in Cambodia: a randomised open-label efficacy study. | 2025 |
| Primaquine | Chemical | associate |
Operational effectiveness of tafenoquine and primaquine for the prevention of Plasmodium vivax recurrence in Brazil: a retrospective observational study. | 2024 |
| Primaquine | Chemical | associate |
Operational feasibility of Plasmodium vivax radical cure with tafenoquine or primaquine following point-of-care, quantitative glucose-6-phosphate dehydrogenase testing in the Brazilian Amazon: a real-life retrospective analysis. | 2024 |
| Primaquine | Chemical | associate |
Negligible Impact of Mass Screening and Treatment on Mesoendemic Malaria Transmission at West Timor in Eastern Indonesia: A Cluster-Randomized Trial. | 2018 |
Showing 5 of 46 relation assertions.
Organizations publishing (338)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Mahidol University | Academic | 30 | 2012 to 2023 |
| University of London | Academic | 22 | 2008 to 2022 |
| University of Oxford | Academic | 22 | 2008 to 2023 |
| Government of the United States of America | Government | 15 | 2008 to 2020 |
| Radboud University Medical Center | Hospital | 14 | 2007 to 2022 |
Showing 5 of 338 organizations.
Where G6PD appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- integumentary system disease
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- reproductive system or breast disease
- respiratory or thoracic disease
- urinary system disease
280 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and human sample screening reference.